Waterdrop first-quarter revenue skyrockets 64%
Waterdrop (NYSE:WDH) recorded net operating revenue of RMB1,242.2 million for the first quarter, representing a 64.8% year-over-year increase.
Todas as matérias desta seção, das mais recentes às mais antigas — página 152 de 371.
Waterdrop (NYSE:WDH) recorded net operating revenue of RMB1,242.2 million for the first quarter, representing a 64.8% year-over-year increase.
SCHMID Group (NASDAQ:SHMD) secured more than €26 million in new technology equipment orders since mid-May 2026.
Brent Crude futures fell 1.7% to a three-month low of $81.73 a barrel on Tuesday.
This decline extended a 5% drop from Monday triggered by news of a preliminary peace agreement.
SpaceX (NASDAQ:SPCX) shares rose 10.1% in premarket trading to reach $211.8 on Tuesday.
This move extended a post-initial public offering rally after the stock climbed more than 19% on Monday.
Teledyne Technologies (NYSE:TDY) announced the release of three military vehicle vision systems featuring 1280p sensors for target detection.
Ballard Power Systems (NASDAQ:BLDP) secured a 15-megawatt order of fuel cell systems to expand its deployment of stationary off-grid power solutions for a renewable energy customer.
Uxin (NASDAQ:UXIN) reported total revenues of RMB1,073.7 million for the quarter ended March 31, 2026.
Pasithea Therapeutics (NASDAQ:KTTA) expanded its Phase 1/1b PAS-004 clinical trial protocol to evaluate higher 24mg and 32mg dose levels.
BitVentures (NASDAQ:BVC) reported its unaudited financial results for the first half of fiscal 2026 ended December 31, 2025.
U.S. data analytics provider Databricks announced an agreement on Tuesday to purchase cybersecurity startup Panther Labs.
Dave & Buster’s (NASDAQ:PLAY) announced its financial results for the first quarter of fiscal 2026 ended May 5, 2026, reporting revenue of $559.2 million and a comparable store sales decline of 5.4%.
High Tide (NASDAQ:HITI) announced its financial results for the three months ended April 30, 2026, highlighting record revenue of $179.3 million and a fourth consecutive quarter of record-breaking performance.
A federal judge in San Francisco dismissed the lawsuit brought by xAI (a subsidiary of SpaceX) against OpenAI, stating that the plaintiff failed to show any actionable misconduct or trade secret theft.
iHeartMedia (NASDAQ:IHRT) and Netflix (NASDAQ:NFLX) announced an expansion of their exclusive video podcast agreement to include new shows from prominent creators such as Kate Hudson, Oliver Hudson, Lele Pons, and Martha Stewart.
Neurocrine Biosciences (NASDAQ:NBIX) presented two-year pediatric data for its CRENESSITY therapy at the ENDO 2026 medical conference.
enGene Therapeutics (NASDAQ:ENGN) announced its financial results for the second quarter ended April 30, 2026, alongside updates on its clinical development pipeline.
Elicio Therapeutics (NASDAQ:ELTX) announced results from its randomized Phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in patients with mKRAS-driven pancreatic ductal adenocarcinoma.
Precigen (NASDAQ:PGEN) has been granted FDA orphan drug exclusivity for its product PAPZIMEOS, used to treat adult recurrent respiratory papillomatosis.
Salesforce (NYSE:CRM) announced it will acquire Fin, formerly known as Intercom, for approximately $3.6 billion to accelerate its position in the autonomous agent market.
Humacyte (NASDAQ:HUMA) announced that its Phase 3 V012 study met its primary superiority endpoint, showing the company’s acellular tissue engineered vessel (ATEV) significantly reduces time spent on dialysis catheters.
TuHURA Biosciences (NASDAQ:HURA) announced today that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to advance its TBS-2025 therapy.
Paranovus Entertainment Technology (NASDAQ:PAVS) executed a non-binding letter of intent to acquire Jabanero for a proposed all-cash purchase price of $15 million to $20 million.
Jerash Holdings (NASDAQ:JRSH) reported record full-year fiscal 2026 revenue of $166.3 million following a 46.6% surge in fourth-quarter sales.
Alkermes plc (NASDAQ:ALKS) announced that its investigational oral medication, alixorexton, was granted orphan drug designations by regulatory authorities in the United States and Europe for rare sleep disorders.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade